There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Enhancing Lung Cancer Screening Through Human-Centered Intervention
NCT06351085
Recruiting
The purpose of this study is to further understand the factors involved in increasing lung cancer screening.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/01/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Lung Cancer
Register for Updates
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
NCT05126758
Recruiting
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during the first 12-months of the study. Al... Read More
Gender:
Male
Ages:
10 years and above
Trial Updated:
03/29/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
Register for Updates
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02408861
Recruiting
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory), or solid tumors that have spread from where it first started to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm
Register for Updates
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
NCT05172960
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
Gender:
All
Ages:
All
Trial Updated:
03/29/2024
Locations: UC Davis Medical Center Sacramento, Sacramento, California
Conditions: Aortic Stenosis, Severe
Register for Updates
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Recruiting
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lym... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Hematological Malignancies
Register for Updates
A Phase 1 Study of Engineered Donor Grafts (Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695
Recruiting
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2024
Locations: UC Davis, Sacramento, California
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: University of California Davis Comprehensive Center, Sacramento, California
Conditions: Select Advanced Solid Tumors
Register for Updates
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (FOX)
NCT06100887
Recruiting
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Gender:
Male
Ages:
Between 6 years and 14 years
Trial Updated:
03/26/2024
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926
Recruiting
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 3 years after enrollment. Additional participant data will be collected from the time the indiv... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
03/26/2024
Locations: University of California, Davis Health Dept of PM&R, Sacramento, California
Conditions: Limb-girdle Muscular Dystrophy
Register for Updates
Examining the Effectiveness of the Early Start Denver Model in Community Programs Serving Young Autism
NCT06005285
Recruiting
This study tests the effectiveness of the Early Start Denver Model (ESDM) in community agencies that serve young autistic children. The feasibility, usability and acceptability of the model will be explored. Understanding effectiveness of new evidence-based models will increase the quality of autism care available to more diverse children and families in more geographic locations.
Gender:
All
Ages:
12 months and above
Trial Updated:
03/26/2024
Locations: University of California, Davis MIND Institute, Sacramento, California
Conditions: Autism
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Sacramento, California
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2024
Locations: Regents of the University of California, Davis, DBA University of California, Davis, Sacramento, California
Conditions: Diabetic Retinopathy
Register for Updates